CA2612417A1 - Anti-gfralpha3 antibodies - Google Patents

Anti-gfralpha3 antibodies Download PDF

Info

Publication number
CA2612417A1
CA2612417A1 CA002612417A CA2612417A CA2612417A1 CA 2612417 A1 CA2612417 A1 CA 2612417A1 CA 002612417 A CA002612417 A CA 002612417A CA 2612417 A CA2612417 A CA 2612417A CA 2612417 A1 CA2612417 A1 CA 2612417A1
Authority
CA
Canada
Prior art keywords
seq
antibody
amino acid
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002612417A
Other languages
English (en)
French (fr)
Inventor
Dane S. Worley
Dinah Wen-Yee Sah
Katherine W. Seamans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2612417A1 publication Critical patent/CA2612417A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002612417A 2005-06-17 2006-06-16 Anti-gfralpha3 antibodies Abandoned CA2612417A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69185005P 2005-06-17 2005-06-17
US60/691,850 2005-06-17
PCT/US2006/023821 WO2006138721A1 (en) 2005-06-17 2006-06-16 Anti-gfralpha3 antibodies

Publications (1)

Publication Number Publication Date
CA2612417A1 true CA2612417A1 (en) 2006-12-28

Family

ID=37570787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002612417A Abandoned CA2612417A1 (en) 2005-06-17 2006-06-16 Anti-gfralpha3 antibodies

Country Status (5)

Country Link
US (1) US20090202562A1 (https=)
EP (1) EP1896047A4 (https=)
JP (1) JP2008546716A (https=)
CA (1) CA2612417A1 (https=)
WO (1) WO2006138721A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
MX2021012335A (es) * 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
EP4406972A4 (en) * 2021-09-24 2025-12-31 Daegu Gyeongbuk Inst Science & Tech GFRAL ANTAGONIST ANTIBODY WITH IMPROVED AFINITY, AND ITS USE
KR102864956B1 (ko) * 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
EP0962467A4 (en) * 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins

Also Published As

Publication number Publication date
JP2008546716A (ja) 2008-12-25
EP1896047A4 (en) 2009-07-22
EP1896047A1 (en) 2008-03-12
WO2006138721A1 (en) 2006-12-28
US20090202562A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
DK2460831T3 (en) TWEAK binding antibodies
CN112041339B (zh) 用于治疗自身免疫病的抗ifnar1抗体
US20090324602A1 (en) Anti-fn14 antibodies and uses thereof
WO2017062672A2 (en) Anti-trem2 antibodies and methods of use thereof
KR20150018533A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
US20230183341A1 (en) Methods of use of anti-trem2 antibodies
BRPI1014016B1 (pt) anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos.
KR20200123170A (ko) B7-h4 항체 제형
US20250084165A1 (en) Methods of use of anti-trem2 antibodies
AU2020291527A1 (en) Anti-Sortilin antibodies for use in therapy
CA2824089A1 (en) Selection and treatment of subjects
US20090202562A1 (en) Anti-gfralpha3 antibodies
CA2599967C (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2015057939A1 (en) Anti-s1p4 antibodies and uses thereof
AU2013200995B2 (en) Tweak binding antibodies
CN119110807A (zh) 抗cd40抗体及其用途
MX2007014935A (en) Tweak binding antibodies

Legal Events

Date Code Title Description
FZDE Dead